ANI Pharmaceuticals Inc. Files Definitive Proxy Statement

TL;DR

<b>ANI Pharmaceuticals Inc. files its Definitive Proxy Statement for the fiscal year ending December 31, 2023.</b>

AI Summary

ANI PHARMACEUTICALS INC (ANIP) filed a Proxy Statement (DEF 14A) with the SEC on April 5, 2024. Filing is a DEF 14A for the fiscal year ending December 31, 2023. Company name is ANI PHARMACEUTICALS INC, Central Index Key 0001023024. Standard Industrial Classification is Pharmaceutical Preparations [2834]. Business address is 210 Main Street West, Baudette, MN 56623. The filing includes data related to executive compensation and equity awards for the years 2020-2023.

Why It Matters

For investors and stakeholders tracking ANI PHARMACEUTICALS INC, this filing contains several important signals. This filing provides shareholders with crucial information regarding executive compensation, director elections, and other corporate governance matters, enabling informed voting decisions. The detailed breakdown of equity awards granted and vested over several years offers insight into the company's long-term incentive strategies and executive remuneration policies.

Risk Assessment

Risk Level: low — ANI PHARMACEUTICALS INC shows low risk based on this filing. The filing is a routine proxy statement (DEF 14A) and does not contain new financial performance data or significant operational updates, indicating a low level of immediate risk.

Analyst Insight

Review the executive compensation details and any proposed shareholder resolutions to understand potential impacts on corporate governance and shareholder value.

Key Numbers

• 2023-12-31 — Fiscal Year End (Conformed Period of Report)
• 2024-04-05 — Filing Date (Filed as of Date)
• 2023 — Reporting Year (Fiscal Year End)
• 2020-2023 — Years of Equity Award Data (Executive Compensation Data)

Key Players & Entities

• ANI PHARMACEUTICALS INC (company) — Filer name
• 0001023024 (company) — Central Index Key
• 2834 (company) — Standard Industrial Classification
• 210 MAIN STREET WEST (company) — Business Address
• BAUDETTE (company) — City
• MN (company) — State
• 56623 (company) — ZIP Code
• Nikhil Lalwani (person) — Executive Compensation/Equity Awards

FAQ

Industry Context

ANI Pharmaceuticals Inc. operates within the pharmaceutical preparations industry, focusing on the development, manufacturing, and marketing of branded and generic prescription pharmaceuticals.

Regulatory Implications

This filing is a routine proxy statement (DEF 14A) required under the Securities Exchange Act of 1934, providing information to shareholders for annual meetings.

What Investors Should Do

1. Review the detailed executive compensation packages and any proposed amendments.
2. Analyze director nominations and voting recommendations.
3. Examine any shareholder proposals and the company's stance on them.

Year-Over-Year Comparison

This is a DEF 14A filing for the fiscal year ending 2023, providing information typically found in annual proxy statements, rather than a quarterly or annual financial report.

Key Financial Figures

• $486.8 million — r record performance in 2023. We posted $486.8 million in total revenue for the year, an incre
• $133.8 m — . Adjusted non-GAAP EBITDA was a record $133.8 million, up 140% year-over-year, and adju
• $4 — djusted non-GAAP earnings per share was $4.71, an increase of 247% from 2022. We g
• $119.0 million — ncrease of 247% from 2022. We generated $119.0 million in cash from operations, resulting in a
• $112.1 million — h trajectory with reported net sales of $112.1 million in 2023, a year-over-year increase of 1
• $270 million — lies that accounted for sales of nearly $270 million in 2023, with our largest product accou
• $0.0001 — s Series A Convertible Preferred Stock, $0.0001 par value per share (the "Series A Pref

Filing Documents

• anip-20240405.htm (DEF 14A) — 1243KB
• anip-20240405_g1.jpg (GRAPHIC) — 60KB
• anip-20240405_g10.jpg (GRAPHIC) — 79KB
• anip-20240405_g11.jpg (GRAPHIC) — 75KB
• anip-20240405_g12.jpg (GRAPHIC) — 828KB
• anip-20240405_g13.jpg (GRAPHIC) — 210KB
• anip-20240405_g2.jpg (GRAPHIC) — 36KB
• anip-20240405_g3.jpg (GRAPHIC) — 18KB
• anip-20240405_g4.jpg (GRAPHIC) — 239KB
• anip-20240405_g5.jpg (GRAPHIC) — 93KB
• anip-20240405_g6.jpg (GRAPHIC) — 2KB
• anip-20240405_g7.jpg (GRAPHIC) — 2KB
• anip-20240405_g8.jpg (GRAPHIC) — 3KB
• anip-20240405_g9.jpg (GRAPHIC) — 2KB
• 0001023024-24-000037.txt (&nbsp;) — 6026KB
• anip-20240405.xsd (EX-101.SCH) — 4KB
• anip-20240405_def.xml (EX-101.DEF) — 6KB
• anip-20240405_lab.xml (EX-101.LAB) — 8KB
• anip-20240405_pre.xml (EX-101.PRE) — 5KB
• anip-20240405_htm.xml (XML) — 271KB

Forward-Looking Statements

Forward-Looking Statements In this communication we have made certain forward-looking statements within the meaning of the federal securities laws. These statements are based on management's estimates and assumptions and are subject to risks and uncertainties. Such statements include, but are not limited to, statements about the Company's corporate strategy, growth strategy, future plans, and other statements that are not historical in nature, particularly those that utilize terminology such as "anticipates," "will," "expects," "plans," "potential," "future," "believes," "intends," "continue," other words of similar meaning, derivations of such words and the use of future dates. These statements are subject to a variety of risks and uncertainties that could cause actual results to differ materially from expectations. These risks and uncertainties include, but are not limited to, the risks detailed in our filings with the Securities and Exchange Commission, including the Risk Factors section of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. The Company gives no assurance that it will achieve its expectations. ANI Pharmaceuticals, Inc. 210 Main Street West Baudette, Minnesota 56623 (218) 634-3500 NOTICE OF 2024 ANNUAL MEETING OF STOCKHOLDERS To Be Held Tuesday, May 21, 2024, 9:00 A.M. (Eastern Time) Virtual Meeting Only—No Physical Meeting Location TIME AND DATE 9:00 A.M. Eastern Time on Tuesday, May 21, 2024, virtual PLACE www.virtualshareholdermeeting.com/ANIP2024 AGENDA Elect the eight director nominees named in the Proxy Statement Ratify the appointment of EisnerAmper LLP as our independent registere

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 23 PROPOSAL 3: ADVISORY (NON-BINDING) VOTE TO APPROVE EXECUTIVE COMPENSATION 46 PROPOSAL 4: APPROVAL OF THE AMENDED AND RESTATED 202 2 STOCK INCENTIVE PLAN 47 PRINCIPAL STOCKHOLDERS 60 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 63 OTHER MATTERS 64 ADDITIONAL INFORMATION 64 i ANI Pharmaceuticals, Inc. 210 Main Street West Baudette, Minnesota 56623 (218) 634-3500 ________________________ PROXY STATEMENT FOR 2024 ANNUAL MEETING OF STOCKHOLDERS To Be Held at 9:00 A.M. Eastern Time on Tuesday, May 21, 2024 ________________________ Our Board of Directors (the "Board") solicits your proxy for the 2024 Annual Meeting of Stockholders (the "Annual Meeting") and any postponement or adjournment of the Annual Meeting for the matters set forth in "Notice of 2024 Annual Meeting of Stockholders." The Annual Meeting will be held virtually on Tuesday, May 21, 2024 at 9:00 A.M. Eastern Time at www.virtualshareholdermeeting.com/ANIP2024 . This Proxy Statement is being made available to holders of the Company's Series A Convertible Preferred Stock, $0.0001 par value per share (the "Series A Preferred Stock"),the Company's Common Stock, $0.0001 par value per share (the "Common Stock") and the Company's Class C Special Stock, $0.0001 par value per share (the "Class C Special Stock" and the holders of the Series A Preferred Stock, the Common Stock and the Class C Special Stock together, the "Stockholders") beginning on April 5, 2024. 1 INFORMATION ABOUT THE ANNUAL MEETING AND VOTING Record Date March 27, 2024 Quorum Requirement Holders of at least one-third of the outstanding shares of the Company's capital stock issued and outstanding and entitled to vote on the record date must be present at the Annual Meeting or represented by proxy. Abstentions and broker non-votes are counted as present and entitled to vote for purposes of determining a quorum. Voting Shares Outstanding on the Record Date 25,000 shares of Serie

View Full Filing

View this DEF 14A filing on SEC EDGAR